Verona Pharma to Present at H.C. Wainwright BioConnect Virtual Conference
Verona Pharma (Nasdaq: VRNA) announced that David Zaccardelli, Pharm.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Verona Pharma (Nasdaq: VRNA) announced that David Zaccardelli, Pharm. D., the CEO, will present an overview of the company at the H.C. Wainwright BioConnect Virtual Conference. The presentation will be available on-demand from 7:00 AM EST / 12:00 PM GMT on January 10, 2022. Interested parties can access a webcast of the event for 90 days via the company's website's Investors page. Verona Pharma focuses on developing innovative therapies for respiratory diseases, with its product candidate ensifentrine currently in Phase 3 development for COPD.
Details
News Market Reaction – VRNA
The recorded move for VRNA in the trading session of this news was +0.29%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LONDON and RALEIGH, N.C., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Pharm. D., President and Chief Executive Officer, will present a company overview at the H.C. Wainwright BioConnect Virtual Conference. The presentation will be available on-demand starting at 7:00 AM EST / 12:00 PM GMT on Monday, January 10, 2022.
A webcast of the event will be available for 90 days on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com.
For further information please contact:
| Verona Pharma plc | US Tel: +1-833-417-0262 UK Tel: +44 (0)203 283 4200 |
| Victoria Stewart, Director of Investor Relations and Communications | info@veronapharma.com |
| Argot Partners (US Investor Enquiries) | Tel: +1-212-600-1902 verona@argotpartners.com |
| Kimberly Minarovich / Michael Barron | |
| Optimum Strategic Communications (International Media and European Investor Enquiries) | Tel: +44 (0)203 950 9144 verona@optimumcomms.com |
| Mary Clark / Stella Lempidaki / Zoe Bolt |
About Verona Pharma
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma’s product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) for COPD maintenance treatment. Two additional formulations of ensifentrine are in Phase 2 development for the treatment of COPD: dry powder inhaler (“DPI”) and pressurized metered-dose inhaler (“pMDI”). Ensifentrine has potential applications in cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.